May 19, 2026 ScienceAccelerating discovery of liver disease mechanisms ShareBiomedical research produces a flood of information that no scientist can realistically absorb. At the University of Edinburgh, bioengineer Filippo Menolascina is using Co-Scientist to comb the literature for overlooked links and generate new hypotheses.His team focused on a common liver disease called metabolic dysfunction‑associated steatohepatitis (MASH). Developing treatments is challenging because MASH involves intertwined biological processes, including liver inflammation and metabolism, meaning single‑target drugs fall short. That pushes researchers toward combination treatments, but the number of potential drug pairings is overwhelming.Faced with that combinatorial explosion, Menolascina used Co‑Scientist to narrow the search. In his hands, Co‑Scientist synthesised evidence across liver biology and pharmacology, highlighted mechanisms worth focusing on, and flagged candidate combination therapies that his team could test.In one emblematic case, Co‑Scientist tackled a live, practical question: Why does the drug resmetirom – a recently approved treatment prescribed for a specific stage of MASH – only help a narrow slice of those eligible patients? The system produced a hypothesis pinpointing the NLRP3 inflammasome as the specific molecular bridge coupling inflammation and metabolism in the disease — a connection never previously pulled together into a single, actionable explanation. The hypothesis, later experimentally verified, could pave the way for targeted dual-therapies.Co‑Scientist feels like a jetpack for scientists, powering up our ability to identify promising mechanisms. I think we’re on the brink of a scientific revolution that will significantly shorten the iteration cycles needed to achieve breakthroughs Professor Filippo Menolascina University of Edinburgh Related postsCo-Scientist: A multi-agent AI partner to accelerate researchMay 2026Science Learn more Uncovering repurposed medicines to fight liver fibrosisMay 2026Science Learn more Uniting biological toolkits for a new approach to ALSMay 2026Science Learn more Opening new paths in aging researchMay 2026Science Learn more Finding the molecular switches behind new infectious diseasesMay 2026Science Learn more Fast-tracking genetic leads to reverse cellular agingMay 2026Science Learn more
Co-Scientist
Breakthroughs in liver disease research
Related
ResearchLearning When to Trust via Selective Context Preference Optimization
Language models increasingly condition their answers on external signals, and a single misleading one can turn a correct answer wrong. The obvious remedy, training models to resist such signals, hides a failure mode: a model that ignores all context looks robust yet is useless when the context is worth trusting. We recast the problem as selective trust and introduce MIST, a human-annotated benchmark that renders each reasoning item under four matched conditions (clean, misleading, correct-context, and irrelevant-context), together with SC2W, a paired metric counting how often a misle
Learning When to Trust via Selective Context Preference Optimization
Language models increasingly condition their answers on external signals, and a single misleading one can turn a correct answer wrong. The obvious remedy, tr...
ResearchTracing the Heart: An Evidence-Linked Pipeline for Heart-Failure Feature Engineering
Electronic health record (EHR) feature engineering is a major bottleneck in clinical research and AI, accounting for 39-45% of data scientists' workload. This is especially pronounced in heart failure, which affects an estimated 6.7 million U.S. adults and requires integrating fragmented EHR data with disease-specific, guideline-based clinical reasoning. Existing rule-based and large language model (LLM)-based approaches offer only partial automation with limited maintainability and evidence traceability. We developed the Nimblemind Multi-Agent System (nMAS), an evidence-linked, rubr